Effect of sildenafil citrate on women affected by sexual dysfunction referred to health clinics

• Authors: Zeinalzadeh Sanaz , Akbarzadeh Marzieh , Faridi Pouya , Mohagheghzadeh Abdol Ali , Sayadi Mehrab
• Languages of publication: EN

Keywords

EN

female; sexual; dysfunction; sildenafil citrate.

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2017
• Issue: 2
• Pages: 167-172

Contributors

author

Zeinalzadeh Sanaz

author

Akbarzadeh Marzieh

author

Faridi Pouya

author

Mohagheghzadeh Abdol Ali

author

Sayadi Mehrab

References

• Basson R. Women’s sexual dysfunction: revised and expanded definitions. CMAJ 2005; 172(10): 1327–1333. Review.
• Zhang H, Yip PS. Female sexual dysfunction among young and middle-aged women in Hong Kong: prevalence and risk factors. J Sex Med 2012; 9(11): 2911–2918.
• Hassanin IM, Helmy YA, Fathalla MM, et al. Prevalence and characteristics of female sexual dysfunction in a sample of women from Upper Egypt. Int J Gynaecol Obstet 2010; 108(3): 219–223.
• Safarinejad M. Female sexual dysfunction in a population-based study in Iran: prevalence and associated risk factors. Int J Impot Res Upper Egypt. Int J Gynaecol Obstet 2010; 108(3): 219–223.
• Ghanbarzadeh N, Nadjafi-Semnani M, Ghanbarzadeh MR, et al. Female sexual dysfunction in Iran: study of prevalence and risk factors.Arch Gynecol Obstet 2013; 287(3): 533–539.
• Aslan E, Beji NK, Gungor I, et al. Re: Prevalence and risk factors for low sexual function in women: a study of 1,009 women in an outpatient clinic of a university hospital in Istanbul-a response. J Sex Med 2009; 6(5): 1491–1492.
• Khan MA, Mikhailidis DP, Morgan RJ. Sildenafil: urologist’s view. Curr Med Res Opin 2000; 16(Suppl. 1): S48–S58.
• D’Amati G, di Gioia CR, Bologna M, et al. Type 5 phosphodiesterase expression in the human vagina. Urology 2002; 60(1): 191–195.
• Rosen RC. Assessment of female sexual dysfunction. Review of validated methods. Fertil Steril 2002; 77(Suppl. 4): S89–S93. Review.
• Nowosielski K, Wróbel B, Sioma-Markowska U, et al. Development and validation of the Polish Version of the Female Sexual Function Index in the Polish population of females. J Sex Med 2013; 10(2): 386–395.
• Isidori AM, Pozza C, Esposito K, et al. Development and Validation of a 6-Item Version of the Female Sexual Function Index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med 2009; 7(3): 1139–1146.
• Mohammadi H, Heidari M, Faghihzadeh S. The Female Sexual Function Index (FSFI): validation of the Iranian version. Faslnameh Payesh 2008; 7(2): 269–278 (in Persian).
• Seftel AD, Padma-Nathan H, McMahan CG, et al. Male and female sexual dysfunction. Edinburgh: Mosby; 2004.
• Kadioglu P, Yalin AS, Tiryakioglu O, et al. Sexual dysfunction in women with hyperprolactinemia: a pilot study report. J Urol 2005;174(5): 1921–1925.
• Atis G, Dalkilinc A, Altuntas Y, et al. Sexual dysfunction in women with clinical hypothyroidism and subclinical hypothyroidism. J Sex Med 2010; 7(7): 2583–2590
• Berman JR, Berman LA, Toler SM, et al. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder:a double-blind, placebo controlled study. J Urol 2003; 170(6 Pt 1): 2333–2338.
• Alexander MS, Rosen RC, Steinberg S, et al. Sildenafil in women with sexual arousal disorder following spinal cord injury. Spinal Cord 2011; 49(2): 273–279.
• Sipski ML, Rosen RC, Alexander CJ, et al. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury.Urology 2000; 55(6): 812–815.
• Salerian AJ, Deibler WE, Vittone BJ, et al. Sildenafil for psychotropic-induced sexual dysfunction in 31 women and 61 men. J Sex Marital Ther 2000; 26(2): 133–140.
• Cavalcanti AL, Bagnoli VR, Fonseca AM, et al. Effect of sildenafil on clitoral blood flow and sexual response in postmenopausal women with orgasmic dysfunction. Int J Gynaecol Obstet 2008; 102(2):115–119
• Ferrara D, Zaslau S. Success of sildenafil treatment in neurogenic female sexual dysfunction caused by L5-S1 intervertebral disk rupture: a case report. Int J Urol 2007; 14(6): 566–567.
• Caruso S, Rugolo S, Agnello C, et al. Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil Steril 2006; 85(5): 1496–1501.
• Chivers M, Rosen R. Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms? J Sex Med 2010;7(2 Pt 2): 858–872.
• Caruso S, Intelisano G, Lupo L, et al. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG 2001; 108(6): 623–628.
• Dasgupta R, Wiseman OJ, Kanabar G, et al. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis.J Urol 2004; 171(3): 1189–1193.
• Moreira SG, Brannigan JRE, Spitz A, et al. Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 2000; 56(3): 474––476.
• Bancroft J. The endocrinology of sexual arousal. J Endocrinol 2005; 186(3): 411–427.
• D’Amati G, di Gioia CR, Bologna M, et al. Type 5 phosphodiesterase expression in the human vagina. Urology 2002; 60(1): 191–195.
• Bitzer J, Brandenburg U. Psychotherapeutic interventions for female sexual dysfunction. Maturitas 2009; 63(2): 160–163